Free Immunoglobulin Light Chains in Patients With Myocarditis: a New Biomarker of Inflammation and Heart Failure

Aim. To study the concentration of immunoglobulin free light chains (FLCs) in patients with myocarditis in comparison with non-inflammatory heart diseases, their relationship with inflammatory markers and the severity of chronic heart failure (CHF).

Material and methods. This study included 77 patients (31 women, mean age 54.1±13.3 years): 41 patients with myocarditis verified by myocardial biopsy (n=18) or using a noninvasive diagnostic algorithm, 31 patients with noninflammatory CHF (comparison group), and 5 patients with monoclonal gammopathy identified during the study (4 of them were diagnosed with AL amyloidosis with heart damage). In the myocarditis group, CHF was diagnosed in 29 patients, mean stage IIA, functional class (FC) 2-3, with a mean left ventricular ejection fraction 43%. In the comparison group, patients had predominantly IIA stage, FC 2-3 CHF without systolic dysfunction. The blood concentration of kappa and lambda FLC types was measured with Cloneus S-FLC-K TIA Kit and Cloneus S-FLC–L TIA Kit. Concentrations were considered normal at FLC-kappa 4.84-14.20 mg/l, FLC-lambda 7.03-22.50 mg/l, and the FLC-kappa/lambda ratio 0.426-1.050.

Results. Increased FLC concentrations were found in 58% of patients with myocarditis and in 77% of patients in the comparison group. The FLC-lambda concentration was significantly higher in the comparison group; there were no significant differences between the groups in FLC-kappa and their ratio. The closest significant correlations in both groups and the entire cohort were noted between FLCs of either type and CHF, as well as the requirement for loop diuretics (correlation coefficients, 0.60-0.90), independent on the severity of systolic dysfunction. Myocarditis patients also showed correlations of FLCs with the titer of antibodies to cardiomyocyte nuclear antigens, levels of C-reactive protein, leukocytes, neutrophils, erythrocyte sedimentation rate, and the concentration of N-terminal fragment of brain natriuretic peptide. In a subgroup of 10 myocarditis patients who were treated with immunosuppressants, FLCs of both types were significantly lower than in the comparison group; only with the persistence of severe CHF was an increase in FLCs noted.

Conclusion. An increased FLC concentration can be considered as an important pathogenesis component that reflects both the specific mechanisms of myocarditis and the severity of CHF. In the absence of a statistically significant increase in general inflammatory markers in the blood of myocarditis patients, the measurement of FLCs can be used as an additional diagnostic marker and predictor of the decompensated variant of the course of myocarditis. However, the diagnostic and prognostic significance of FLC concentration in patients without CHF requires a further study.

1. Blagova O.V., Osipova Yu.V., Nedostup A.V., Kogan E.A., Sulimov V.A. Clinical, laboratory and instrumental criteria for myocarditis, established in comparison with myocardial biopsy: A non-invasive diagnostic algorithm. Therapeutic Archive. 2017;89(9):30–40. DOI: 10.17116/terarkh201789930-40

2. Blagova O.V., Nedostup A.V., Kogan E.A. Myocardial and pericardial diseases: from syndromes to diagnosis and treatment. - M.: GEOTAR-Media, 2019. - 884p. ISBN 978-5-9704-4743-7

3. Arutyunov G.P., Paleev F.N., Moiseeva O.M., Dragunov D.O., Sokolova A.V., Arutyunov A.G. et al. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):136–82. DOI: 10.15829/1560-4071-2021-4790

4. Tschöpe C, Van Linthout S, Spillmann F, Posch MG, Reinke P, Volk H-D et al. Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. European Heart Journal - Case Reports. 2019;3(3):ytz131. DOI: 10.1093/ehjcr/ytz131

5. Rao A, Gupta A, Kain V, Halade GV. Extrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure. American Journal of Physiology-Heart and Circulatory Physiology. 2023;325(3):H433–48. DOI: 10.1152/ajpheart.00276.2023

6. Matsumori A, Shimada T, Nakatani E, Shimada M, Tracy S, Chapman NM et al. Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clinical Immunology. 2020;217:108455. DOI: 10.1016/j.clim.2020.108455

7. Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A et al. Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. JACC: Heart Failure. 2015;3(8):618–25. DOI: 10.1016/j.jchf.2015.03.014

8. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. Journal of the American College of Cardiology. 2018;72(24):3158–76. DOI: 10.1016/j.jacc.2018.09.072

9. Matsumori A, Shimada M, Jie X, Higuchi H, Kormelink TG, Redegeld FA. Effects of Free Immunoglobulin Light Chains on Viral Myocarditis. Circulation Research. 2010;106(9):1533–40. DOI: 10.1161/CIRCRESAHA.110.218438

10. Shantsila E, Wrigley B, Lip GYH. Free Light Chains in Patients With Acute Heart Failure Secondary to Atherosclerotic Coronary Artery Disease. The American Journal of Cardiology. 2014;114(8):1243–8. DOI: 10.1016/j.amjcard.2014.07.049

11. Perrone MA, Pieri M, Marchei M, Sergi D, Bernardini S, Romeo F. Serum free light chains in patients with ST elevation myocardial infarction (STEMI): A possible correlation with left ventricle dysfunction. International Journal of Cardiology. 2019;292:32–4. DOI: 10.1016/j.ijcard.2019.06.016

12. Kimishima Y, Yoshihisa A, Kiko T, Yokokawa T, Miyata-Tatsumi M, Misaka T et al. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis. International Heart Journal. 2019;60(5):1106–12. DOI: 10.1536/ihj.19-043

13. Lysenko L.V., Rameev V.V., Moiseev S.V., Blagova O.V., Bogdanov E.I., Gendlin G.E. et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Clinical pharmacology and therapy. 2020;29(1):13–24. DOI: 10.32756/0869-5490-2020-1-13-24

14. Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports. 2017;7(1):15661. DOI: 10.1038/s41598-017-15424-3

15. Kurt İH, Yavuzer K, Batur MK. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. Heart and Vessels. 2010;25(5):392–9. DOI: 10.1007/s00380-009-1216-4